Skip to main content
. Author manuscript; available in PMC: 2022 Jun 14.
Published in final edited form as: Cell Rep. 2022 May 24;39(8):110839. doi: 10.1016/j.celrep.2022.110839

Figure 7. Reduction in effective DAR and payload dose is more prominent in heterogeneous ADCs than in homogeneous ADCs.

Figure 7.

All values used in this figure are estimated values based on the data shown in Figures 1 and 6. Theoretical payload doses of heterogeneous and homogeneous ADCs with the same (average) DAR are equivalent if administered at the same mAb dose. However, high-DAR components in heterogeneous ADCs show poor brain tumor targeting, decreasing the effective DAR and payload dose. Such deterioration is marginal in the case of homogeneous ADCs, leading to improved payload delivery and overall efficacy.